在宅医療市場

The secondary research process involved systematic analysis of regulatory filings, peer-reviewed clinical literature, medical device databases, and authoritative healthcare statistics. Key sources included the Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services (HHS), Food and Drug Administration (FDA) Medical Device Databases, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, European Medicines Agency (EMA), National Health Service (NHS) Digital, World Health Organization (WHO) Global Health Observatory, OECD Health Statistics, National Association for Home Care & Hospice (NAHC), Home Care Association of America (HCAOA), American Association for Respiratory Care (AARC), American Telemedicine Association (ATA), Healthcare Information and Management Systems Society (HIMSS), and national health ministry databases from key markets.

These resources made it easier to gather information on medical device approval records, chronic disease prevalence statistics, telehealth adoption metrics, skilled nursing utilization rates, reimbursement policy data, and demographic aging trends for a variety of home healthcare service categories, such as respiratory therapy, infusion therapy, skilled nursing, rehabilitation therapy, and hospice care.

In order to collect both qualitative and quantitative intelligence, supply-side and demand-side stakeholders were surveyed and interviewed in an organized manner during the main research process. CEOs, COOs, VPs of clinical services, regulatory affairs managers, and commercial leaders from home healthcare organizations, makers of durable medical equipment, suppliers of remote patient monitoring technologies, and developers of telehealth platforms were among the supply-side attendees. Demand-side participants included hospital-at-home program procurement directors, geriatric specialists, certified home health nurses, physical therapists, palliative care coordinators, insurance reimbursement managers, family caregiver representatives, and primary care physicians. Primary study established technology adoption timescales, validated service line segmentation, and collected data on patient choice shifts across testing/monitoring device and therapy service categories, workforce shortage impacts, and reimbursement dynamics.

Primary Respondent Breakdown:

By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Revenue triangulation and service volume analysis across device and service segments were used to determine the global market valuation. The approach included:

Identification of more than fifty important parties, including home health agencies, DME producers, and telehealth providers, throughout North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa

Product and service mapping for skilled nursing services, respiratory treatment, infusion therapy, hospice and palliative care, rehabilitation therapy, and testing/screening/monitoring equipment (blood glucose monitors, blood pressure monitors, pulse oximeters, and fetal monitoring devices).

Analysis of Medicare/Medicaid payment claim data and reported and estimated yearly revenues unique to home healthcare portfolios

coverage of manufacturers and service providers that will account for 72–78% of the worldwide market in 2024

Segment-specific valuations for telemedicine, remote patient monitoring, and traditional home nursing services were obtained by extrapolating using top-down (provider revenue validation) and bottom-up (procedure volume × reimbursement rates by country) approaches, cross-referencing them with government health expenditure databases and insurance claims data.